Toxic Rep Ser. 1994 Aug;40:1-E30.
beta-Bromo-beta-nitrostyrene is a wide-spectrum biocide most frequently used as a fungicide to combat the formation of slime in paper and pulp mill operations. Toxicity studies were conducted by administering beta-bromo-beta-nitrostyrene (99% pure, trans isomer) to groups of 10 male and 10 female F344/N rats and B6C3F1 mice by gavage, 5 days per week for 4 weeks. Doses of 0, 37, 75, 150, 300, or 600 mg/kg were administered in a corn oil vehicle. The parameters evaluated included hematology, clinical chemistry (rats only), and histopathology. The genetic toxicity of b-bromo-b- nitrostyrene was evaluated in Salmonella typhimurium and in peripheral blood erythrocytes of mice. In addition, the absorption, distribution, metabolism, and excretion of b-bromo-b- nitrostyrene were studied in male F344 rats following intravenous, dermal, or oral administration. In the 4-week study in rats, two males in the 150 mg/kg group, one male and one female in the 300 mg/kg groups, and all rats in the 600 mg/kg groups died or were killed moribund before the end of the study. The mean body weight gains and absolute and relative thymus weights of male and female rats in the 300 mg/kg groups were lower than those of the controls. Hematology evaluations in rats indicated the development of a mild anemia and monocytosis consistent with and likely related to inflammatory and ulcerative lesions that occurred in the gastrointestinal tract. Clinical chemistry evaluations indicated lower alkaline phosphatase activities and serum total protein and albumin concentrations in treated rats than in the controls. Treatment-related lesions in rats were observed in the forestomach, glandular stomach, cecum, nasal passages, and testis. Males were generally affected at lower doses than females. The most prominent lesions were in the forestomach and were characterized by inflammation, hemorrhage, and necrosis in rats dying early. In rats surviving to the end of the study, forestomach lesions included necrosis, ulceration, and regenerative epithelial hyperplasia and hyperkeratosis. Inflammation of the glandular stomach and cecum also occurred in rats dying early. Inflammation and degeneration of the nasal passage in treated rats were attributed to reflux of the irritant chemical in the gavage fluid. Testicular degeneration was seen in rats dying early and was characterized by necrotic germ cells and a decreased number of spermatozoa in the epididymal tubules and by multinucleated syncytial cells in the seminiferous tubules. In the 4-week study in mice, one male in the 300 mg/kg group and all mice in the 600 mg/kg groups died or were killed moribund before the end of the study. No significant changes in final mean body weights or mean body weight gains were observed in males or females. Hematologic changes consistent with inflammatory lesions occurred in male and female mice in the 300 mg/kg groups. Treatment-related lesions in mice occurred in the forestomach, gallbladder, and testis. Forestomach lesions were similar to those described in rats and were only present in male and female mice given doses of 300 mg/kg or greater. At these dose levels, inflammation and degeneration/necrosis of the gallbladder mucosa also occurred in male and female mice, but these lesions were absent in the bile ducts or liver. Testicular degeneration occurred in mice dying early and was similar to that observed in rats. In comparative disposition and metabolism studies in male F344 rats, clear differences were found between the fate of b-bromo- b-nitrostyrene following oral administration and the fate of radiolabeled beta-bromo-beta-nitrostyrene following intravenous or dermal administration. Oral exposure resulted in significant absorption of nonhydrolyzed beta-bromo-beta-nitrostyrene and the formation of parent compound metabolites, primarily 1-phenyl-2-nitroethyl-1-sulfonic acid (PNSA), a product of a sulfation reaction at the alpha carbon. Following dermal exposure, a limited amount of beta-bromo-beta-nitrostyrene entered the systemic circulation (approximately 10% per 24 hours from a 10 mg/cm2 dose) although lower doses were more completely absorbed. Once beta-bromo-beta-nitrostyrene entered the circulation, significant amounts of the dose were hydrolyzed or bound to macromolecules. PNSA was not a major metabolite in dermal or intravenous studies. Regardless of the route of administration, only low levels of radioactive label from beta-bromo-beta-nitrostyrene were retained in tissues following exposure, and most beta-bromo-beta-nitrostyrene metabolites were excreted in the urine and feces within 24 to 48 hours. beta-bromo-beta-nitrostyrene was mutagenic in S. typhimurium strains TA98 and TA100 in the absence of exogenous metabolic activation (S9). No mutagenic activity was observed with S9 in either of these strains, and no mutagenic activity was observed in strains TA97 or TA1535, with or without S9. The frequency of micronucleated normochromatic erythrocytes was significantly increased in the peripheral blood of male mice, but not female mice, following 4 weeks of exposure to beta-bromo-beta-nitrostyrene by corn oil gavage. In summary, under the conditions of these 4-week gavage studies, rats were more sensitive to the toxic and irritant effects of beta-bromo-beta-nitrostyrene than mice, and males were more affected by beta-bromo-beta-nitrostyrene than females. Although the specific cause of the early deaths could not be determined, significant inflammation and necrosis developed in the forestomach of rats and mice, in the glandular stomach and cecum of rats, and in the gallbladder of mice. Similar lesions in the nasal passages of rats were attributed to reflux of gavage materials. The no-observed- adverse-effect level (NOAEL) for histopathologic lesions was 37 mg/kg per day for rats and 150 mg/kg per day for mice.
β-溴-β-硝基苯乙烯是一种广谱杀菌剂,最常用于造纸和纸浆厂操作中作为杀真菌剂来对抗黏液的形成。通过将β-溴-β-硝基苯乙烯(99%纯,反式异构体)经口灌胃给予10只雄性和10只雌性F344/N大鼠以及B6C3F1小鼠组,每周5天,共4周,进行了毒性研究。以玉米油为载体给予0、37、75、150、300或600mg/kg的剂量。评估的参数包括血液学、临床化学(仅大鼠)和组织病理学。在鼠伤寒沙门氏菌和小鼠外周血红细胞中评估了β-溴-β-硝基苯乙烯的遗传毒性。此外,在雄性F344大鼠静脉内、皮肤或口服给药后,研究了β-溴-β-硝基苯乙烯的吸收、分布、代谢和排泄。在大鼠的4周研究中,150mg/kg组的2只雄性大鼠、300mg/kg组的1只雄性和1只雌性大鼠以及600mg/kg组的所有大鼠在研究结束前死亡或濒死被处死。300mg/kg组雄性和雌性大鼠的平均体重增加以及绝对和相对胸腺重量低于对照组。大鼠的血液学评估表明出现了轻度贫血和单核细胞增多症,这与胃肠道中发生的炎症和溃疡性病变一致且可能相关。临床化学评估表明,与对照组相比,给药大鼠的碱性磷酸酶活性、血清总蛋白和白蛋白浓度较低。在大鼠的前胃、腺胃、盲肠、鼻道和睾丸中观察到了与治疗相关的病变。雄性一般比雌性在较低剂量时受到影响。最突出的病变在前胃,早期死亡的大鼠表现为炎症、出血和坏死。在存活至研究结束的大鼠中,前胃病变包括坏死、溃疡、再生上皮增生和角化过度。早期死亡的大鼠腺胃和盲肠也出现炎症。给药大鼠鼻道的炎症和变性归因于灌胃液中刺激性化学物质的反流。早期死亡的大鼠出现睾丸变性,其特征是附睾小管中的生精细胞坏死和精子数量减少以及曲细精管中的多核合胞体细胞。在小鼠的4周研究中,300mg/kg组的1只雄性小鼠和600mg/kg组的所有小鼠在研究结束前死亡或濒死被处死。未观察到雄性或雌性最终平均体重或平均体重增加有显著变化。300mg/kg组雄性和雌性小鼠出现了与炎症病变一致的血液学变化。小鼠中与治疗相关的病变发生在前胃、胆囊和睾丸。前胃病变与大鼠中描述的相似,仅在给予300mg/kg或更高剂量的雄性和雌性小鼠中出现。在这些剂量水平下,雄性和雌性小鼠的胆囊黏膜也出现炎症和变性/坏死,但胆管或肝脏中没有这些病变。早期死亡的小鼠出现睾丸变性,与在大鼠中观察到的相似。在雄性F344大鼠的比较处置和代谢研究中,发现口服给予β-溴-β-硝基苯乙烯的命运与静脉内或皮肤给予放射性标记的β-溴-β-硝基苯乙烯的命运之间存在明显差异。口服暴露导致未水解的β-溴-β-硝基苯乙烯大量吸收并形成母体化合物代谢物,主要是1-苯基-2-硝基乙基-1-磺酸(PNSA),这是α碳处硫酸化反应的产物。皮肤暴露后,有限量的β-溴-β-硝基苯乙烯进入体循环(从10mg/cm²剂量每24小时约10%),尽管较低剂量吸收更完全。一旦β-溴-β-硝基苯乙烯进入循环,大量剂量被水解或与大分子结合。在皮肤或静脉内研究中,PNSA不是主要代谢物。无论给药途径如何,暴露后组织中仅保留低水平的β-溴-β-硝基苯乙烯放射性标记,并且大多数β-溴-β-硝基苯乙烯代谢物在24至48小时内随尿液和粪便排出。在没有外源性代谢激活(S9)的情况下,β-溴-β-硝基苯乙烯在鼠伤寒沙门氏菌菌株TA98和TA100中具有致突变性。在这两种菌株中,添加S9均未观察到致突变活性,并且在菌株TA97或TA1535中,无论有无S9均未观察到致突变活性。通过玉米油灌胃暴露4周后,雄性小鼠外周血中微核正染色红细胞的频率显著增加,但雌性小鼠未增加。总之,在这些4周灌胃研究的条件下,大鼠对β-溴-β-硝基苯乙烯的毒性和刺激性作用比小鼠更敏感,并且雄性比雌性受β-溴-β-硝基苯乙烯的影响更大。尽管无法确定早期死亡的具体原因,但大鼠和小鼠的前胃、大鼠的腺胃和盲肠以及小鼠的胆囊中出现了明显的炎症和坏死。大鼠鼻道中的类似病变归因于灌胃物质的反流。组织病理学病变的未观察到有害作用水平(NOAEL)对于大鼠为每天37mg/kg,对于小鼠为每天150mg/kg。